Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MOVE-Lp(a): Muvalaplin outcomes study in adults with elevated lipoprotein(a) and established or high-risk atherosclerotic cardiovascular disease
CTR20253466Phase 3Active
- Sponsor
- Eli Lilly and Company
- Start
- Oct 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of muvalaplin in atherosclerotic disease, hyperlipoproteinemia, sponsored by Eli Lilly and Company. Started Oct 2025; status: active.
02
Drugs
muvalaplin
03
Conditions
atherosclerotic diseasehyperlipoproteinemia
Beyond the preview
Go deeper on CTR20253466.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20253466.